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SECRETORY leucocyte  protease  inhibitor  (SLPI)  is  a
potent  inhibitor  of  granulocyte  elastase  and  cath-
epsin G, and also an inhibitor of pancreatic enzymes
like  trypsin,  chymotrypsin  and  pancreatic  elastase.
SLPI has also been shown to inhibit HIV-1 infections
by  blocking  viral  DNA  synthesis.  Since  SLPI  is  an
inhibitor of pancreatic proteases we wished to inves-
tigate whether SLPI was also actually produced in the
pancreas.  M-RNA  from  human  pancreatic  tissue
showed evidence of SLPI production using the reverse
transcriptase polymer chain reaction technique (RT-
PCR). Using immunohistochemical methods SLPI was
demonstrated in the b -ce1ls of the islets of  Langer-
hans.  The  function  could  be  local  protease/anti-
protease regulation or antiviral/antibacterial defence
in the close vicinity of the cell surface, or even inside
the b -cell itself.
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Introduction
SLPI  is  an  acid-resistant  11.8-kDa  non-glycosylated
serine  antiprotease.  Originally  isolated  from human
parotid  gland  secretions,1 it  is  found  in  cells  on  a
variety of mucosal surfaces. For example, the seminal
vesicles, prostate, epididymis and cervix,2–7 in serous
cells  of  the  parotid  and  submandibular  salivary
glands,1,8,9 in  the  upper  respiratory  tract,  in  the
lacrimal  glands,10 as  well  as  in  the  Clara  cells  and
goblet cells of the lower respiratory tract.11–13 SLPI
has also been found in von Ebner’s glands at the base
of the tongue and submucosal cells of the oesopha-
gus.10 Recently, SLPI was found in Paneth cells in the
small  intestine,  and  in  scattered  mucosa  cells  of
goblet-type in the epithelium of both the large and
small  bowel.  In  addition,  SLPI  has  frequently  been
found in colonic adenomas.14
SLPI is thought to be an inflammatory regulator with
strong  inhibitory  capacity  aimed  towards  proteases
present in various body fluids. Thus, SLPI is a potent
inhibitor of leucocyte elastase and cathepsin G, and a
moderate inhibitor of trypsin and chymotrypsin.1,15,16
Furthermore, it is a moderate inhibitor of pancreatic
elastase,17 and it is also known to inhibit both mast cell
chymase  activity  and  histamine  release  from  mast
cells.18,19 Its proteinase-inhibitory activity is known to
be  located  in  the  second  COOH-terminal  domain.
Although no inhibitory capacity has been detected in
the NH2-terminal domain, antimicrobial capacity has
been reported.20,21 It has also been reported that SLPI
blocks the human immunodeficiency virus type 1 by
blocking DNA synthesis.22 SLPI is probably involved in
inflammatory regulation in the intestines as well as in
the respiratory and urogenital tracts. In patients with
ulcerative  colitis,  active  pancreatic  proteases  have
been found in faeces. Since SLPI is an inhibitor of both
pancreatic  and  leukocytic  proteases,  it  could  be  of
importance in the pathogenesis of ulcerative colitis.
Having recently demonstrated SLPI production in the
intestinal mucosa,14 and knowing that SLPI produced
in the upper respiratory tract is rapidly degraded in
gastric  and  duodenal  juice,23 we  also  wanted  to
investigate other possibilities of origin. Earlier studies
failed to show production or presence of SLPI in the
pancreas.10 The aim of this study was, therefore, to
reinvestigate  the  possible  presence  and  production
of  SLPI  in  pancreatic  tissue  using  more  sensitive
methods.
Methods  and  materials
Xylene, ethanol, hydrochloric acid, hydrogen perox-
idase, formaldehyde, haematoxylin and Tris-buffered
saline  (0.05 mol/l  Tris  in  NaCl  0.15 mol/l,  pH  7.6)
were standard chemicals for laboratory use. Recombi-
nant  human  SLPI  was  a  kind  gift  from  Robert
Thompson at Synergen Inc. (Boulder, CO, USA). Goat
anti-SLPI antiserum was produced in the laboratory by
immunising Swedish landrace goats with recombinant
SLPI.  Normal  goat  and  rabbit  serum  was  obtained
from  Dakopatt  AB  (Copenhagen,  Denmark).  Bio-
tinylated  rabbit  anti-goat  IgG  antibodies  and  avidin-
biotinylated  horseradish  peroxidase  complex  (ABC
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(Burlingame,  CA,  USA).  Diaminobenzidine  was  a
product  of  Saveen  Biotech  AB  (Malm¨ o,  Sweden).
Crystalline3 porcine pepsin was obtained from Sigma
Chemicals (St. Louis, MO, USA).
RT-PCR  and  Southern  blot
Human  pancreas  Poly(A+)  RNA  was  obtained  from
Clontec (Palo Alto, CA, USA). Specific primers (R&D
Systems  Europe  Ltd, Abingdon,  UK)  were  designed
according  to  the  nucleic  acid  sequence  of  SLPI
cDNA.24 The upstream and downstream primers for
amplification  of  the  human  SLPI  cDNA  fragments
were:  59 -TGT  CCT  GAC  ACT  TGT  GGC  AT-39 and
59 -CGA TCA ACT GGC ACT TCT TG-39 . The oligonu-
cleotide used for probing the Southern blot of the RT-
PCR product had the sequence 59 -GGT TTG GGG TGT
CAA CAG GAT CCA GGC AT-39 with the modification
39 +59 digoxigenin.24
The  first  strand  of  cDNA  was  synthesised  using
reverse  transcriptase,  isolated  from  avian  myelo-
blastosis virus (Appligene, Illkirch, France) in a 50-m l
reaction mixture containing 2.5 m l 400 mM Tris–HCl,
pH 8.3, 2.5 m l 400 mM KCl, 1m l 300 mM MgCl2, 5 m l
100 mM dithiothretiol (DTT), 5m l 5 mM 4dNTPmix,
2 m l 2 mg/ml actinomycin D, 1 m l 4 m M downstream
primer and  approx.  1–2 m g poly(A+) RNA  (approx.
10 m l). The reaction mixture was incubated at 42°C for
60 mm,  then  diluted  with  450 m l  10 mM Tris–HCl/
10 mM EDTA, pH 7.5. To 5 m l of this diluted mixture
were added 5 m l of each amplification primer, 20 mM
each, 4 m l 5 mM 4dNTPmix, 10 m l 103 amplification
buffer (500 mM KCl, 100 mM Tris–HCl, pH 8.4, and
1 mg/ml gelatine), 1.5 m l 100 mM MgCl2 and 69 m l H2O.
The PCR reaction was performed using the ‘hot start’
method with paraffin pellets, heating at 94°C for 2 min
followed by chilling on ice. Then 2.5 units (0.5 m l) of
Taq DNA polymerase (Appligene) were added to the
tubes. Amplification was carried out in a thermo-cycler
(Hybaid Omnigene, Teddington, UK) with the follow-
ing cycling programme: 39 cycles of 2 min at 55°C;
2 min at 72°C and 1min at 94°C; followed by one cycle
of 2 min at 55°C and 7min at 72°C. The PCR product
was then analysed by agarose gel electrophoresis and
visualised  after  ethidium  bromide  staining  (0.8%
agarose gel in 0.53 TBE buffer).
The PCR-product was transferred to a Hybond  N
transfer  membrane  (Amersham,  Buckinghamshire,
UK) according to the method of Maniatis et al.26 After
heating  the  membrane  for  30 min  at  80°C,  it  was
prehybridised for 4 h at 42°C in a solution containing
53 standard  saline  citrate  (SSC),  50%  formamide,
0.02% (w/v) sodium dodecylsulfate (SDS), 0.1% (w/v)
N-lauroylsarcosine  and  2%  (w/v)  blocking  reagent
(Boehringer-Mannheim,  Mannheim,  Germany).
Hybridisation  was carried out in the same solution,
including 20 ng probe/ml solution overnight at 42°C.
After hybridisation the membrane was washed in 2
3 SSC containing 0.1% SDS, 1 3 15 min, 0.1 3 SSC
containing  0.1%  SDS,  2  3 15 min,  both  at  room
temperature. Detection of the target DNA hybrid was
achieved as follows. After a brief rinse in 100 mM Tris–
HCl,  150 mM  NaCl,  pH  7.5,  the  membrane  was
incubated in 0.5% (w/v) blocking reagent in the same
buffer for 30min. This was followed by a brief wash in
buffer.  Diluted  anti-digoxigenin  antibody–AP-conju-
gate (1:500) was applied to the membrane for 30 min.
Rinses in  buffer, 2 3 15 min followed. The staining
was  carried  out  by  incubating  the  membrane  in  a
solution containing 45 m l Nitroblue Tetrasodium salt
(NBT), 35m l  5-bromo-4-chloro-33  indolyl  phosphate
(X-phosphate)  in  10 ml  buffer  (100mM  Tris–HCl,
100 mM NaCl, 50 mM MgCl2, pH 9.5). The experiment
was repeated three times.
Immunohistochemical  staining
Pancreas specimens from five different patients col-
lected during surgery for pancreatic adenocarcinoma
were investigated. The specimens were from micro-
and  macroscopically  normal  pancreatic  tissue. The
patients were two men and three women between 41
and 69  years of age. They had no earlier history of
pancreatic disease. Informed consent for the proce-
dure was  obtained. The  tissue samples  were  cut at
random  and  fixed  in  4%  formaldehyde.  Paraffin-
embedded tissue was routinely stained with haema-
toxylin for light microscopic examination. The fixed
specimens were subjected to pepsin digestion (pep-
sin 4 mg/ml in 0.01 mol/l HCl) for 30min at 37°C and
were transferred into Tris-buffered saline. To quench
endogenous  tissue  peroxidase  activity,  in  the  next
step, the sections were incubated with 0.3% H2O2 in
methanol for 30 min at room temperature. To block
non-specific staining, the specimens were incubated
for  10 min  in  5%  normal rabbit  serum.  In  order  to
show specific staining in the b -cells, the specimens
were treated as follows.
(1) SLPI
The slides were incubated with goat anti-human SLPI
(1:1000)  for  30 min  followed  by  the  addition  of
biotinylated  rabbit  anti-goat  IG  antibodies  (5 m g/ml
buffer) for 30 min. This was followed by incubation
with avidin biotinylated horseradish peroxidase com-
plex for 30 min. After the sections were rinsed, the
substrate reaction was performed by incubating the
sections  in  3-amino-9-ethylcarbazole  (AEC;  Dako®
Corporation, Carpinteria, CA, USA) for 25 min. After
final washing the specimens were rinsed in tap water
then  mounted. All  incubations  were  performed  at
room temperature, and specimens were washed three
times  (5min)  between  each  step  with Tris-buffered
saline.  Negative  controls  were  always  incubated  in
parallel with adsorbed anti-SLPI antiserum which had
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SLPI-conjugated  Sepharose  4B  column  (Pharmacia
Fine Chemicals, Uppsala, Sweden). The experiments
were repeated three times.
(2) Insulin
The  procedure  was  identical  with  that  described
above,  except that  a sheep  anti-human insulin anti-
body was used in 1:2000 solution (‘The binding site’,
Birmingham,  UK).  Incubation  was  performed  in
alkaline phosphatase complex instead of avidin bio-
tinylated horseradish peroxidase. For staining, 22.8 m l
NBT and 17 m l BCIP were added to 5 ml buffer.
(3) Double staining
The specimens were first stained for insulin, then the
same specimen was also stained for SLPI, as described
above.
Results
RT-PCR  and  Southern  blot  analysis
Water  was  used  as  a  negative  control,  and  trachea
tissue as a positive control. A characteristic band was
observed in the trachea tissue lane representing SLPI
cDNA fragments. In the lane representing pancreatic
tissue there was specific staining of the correspond-
ing amplified cDNA fragments in the same position,
but somewhat weaker than for the positive tracheal
control.  The  bands  were  distinct  and  the  lanes
contained  no  detectable  signs  of  any  other  bands.
There were no detectable bands in the lane contain-
ing  the  negative  control  (Fig.  1). The  pattern  was
identical in all experiments.
Immunohistochemical  staining
Immunoreactive  SLPI  was  found  using  the  human
anti-SLPI  antibody,  resulting  in  bright  red  staining
clearly concentrated to the islets of Langerhans (Fig.
2A).  Using  human anti-insulin antibodies, immunor-
eactive insulin was found in the b -ce1ls of the islets of
Langerhans, as indicated by distinct blue staining (Fig.
2B). When the specimens were stained first with the
human anti-insulin antibody, and then with the human
anti-SLPI  antibody,  the  original  staining  colours  of
blue and bright red were not observed, but the cells
were stained purple resulting from insulin and SLPI in
the same cell population (Fig. 2C). There was no sign
of  SLPI  staining  when  using  adsorbed  anti-SLPI
antiserum.  The  results  obtained  were  verified  in
triplicate experiments.
Discussion
SLPI is found in many different cell types in man. Its
generally accepted function has hitherto been prote-
ase inhibition, thereby modulating the inflammatory
response. Protection of the ciliated epithelium of the
respiratory  tract  against  the  activity  of  leucocyte
proteases released in purulent infection is assumed to
be one important function of SLPI.15 New properties
of  this  protein  have  recently  been  discovered,  and
there  are  now  reports  indicating  antibacterial  and
antiviral effects.20–22 In the light of these findings, new
mechanisms for SLPI action may be anticipated. This
study shows evidence of SLPI production in the b -cells
of  the  islets  of  Langerhans.  Utilising  the  RT-PCR
technique we first observed SLPI-mRNA in pancreatic
tissue. Using immunohistochemical methods we were
then able to confirm that SLPI is produced in the b -cells
of the islets of Langerhans. The function of SLPI in the
islets  of  Langerlians  is  far  from  clear. The  question
arises of whether SLPI with pancreatic origin is meant
to  act  extracellularly  in  the  traditional  protease
inhibitor manner, or whether it has other functions.
The anti HIV-l activity of SLPI has been shown to take
place early in the viral infection of cells, probably after
virus binding and before reverse transcription.22 Our
finding of SLPI in the pancreatic islets of Langerhans
indicates an auto-/or paracrine function rather than an
SLPI production in human b -cells
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FIG. 1. SLPI cDNA fragments were demonstrated in pan-
creatic tissue using RT-PCR  and  Southern  blot.  C, negative
control containing water; P, pancreatic tissue; T, tracheal
tissue used as a positive control. In the lane representing
pancreatic  tissue  strong  specific  staining  of  the  correspond-
ing  amplified  cDNA  fragments  was  observed.  The  band  is  at
the  same position  but somewhat weaker than  that for the
positive  tracheal  control.  No  bands  were  detected  in  the  lane
containing  the  negative  control.M. Nystr¨ om et al.
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FIG. 2.  Using immunohistochemical  methods  and  staining  with  different  antibody  solutions novel  colour schemes can be
accomplished. (A) The presence of immunoreactive SLPI was demonstrated using a specific human anti-SLPI antibody
resulting  in  a  bright  red  colour  in  the  islets  of  Langerhans.  (B)  Human  anti-insulin  antibodies  showed  blue  staining  in  the  b -cells
of  pancreas  tissue.  (C)  Staining  the  specimens  first  for  insulin  then  for  SLPI  resulted  in  a  purple  colour  indicating  the  presence
of  insulin  and  SLPI  in  the  b -ceIls  of  the  islets  of  Langerhans.
A
B
Cexocrine function. In accordance with findings of anti
HIV-1 activity and antibacterial properties, a possible
function might be the protection of the cells against
viral or bacterial infections. Another possible autocrine
function  could  be  protease/antiprotease  regulation.
Further studies are, however, required to identify the
proteases involved.
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